MGMT and glioblastoma: First, GBM patients with TMZ chemotherapy were separated according to whether they had low expression of either BICD1 or MGMT or both, and high expression of both MGMT and BICD1. Second, the patient group with high expression of both MGMT and BICD1 could be further stratified into 2 distinct risk groups according to age.